Hizentra® is available on the Canadian Blood Services Formulary as a First-Line Treatment Option for PID and SID, and as Maintenance Therapy for CIDP[1]

Hizentra®
Subcutaneous Immunoglobulin (Human), 20%

Introducing the Convenient 50 mL Pre-Filled Syringe (10 g IgG Protein):

The first and only IG available in a pre-filled syringe

Pre-Filled Syringes	
Fill Size (mL)	IgG Protein (g)
50	10
20	4
10	2
5	1

Carton size comparison: Storing 50 mL of Hizentra

Takes Up Less Than Half as Much Shelf Volume as the Same Dose in Smaller Pre-Filled Syringes

50 mL pre-filled syringe

- One box: 106 mm x 50 mm x 185 mm
- Volume of one box: 980,500 mm^3

VS.



- One 20 mL box: 95 mm x 48 mm x 169 mm
- One 10 mL box: 124 mm x 45 mm x 111 mm
- Volume of two 20 mL boxes and one 10 mL box: 2,160,660 mm^3

Two 20 mL pre-filled syringes and a 10 mL pre-filled syringe

Storage instructions:[1]

- Hizentra can be stored either in the refrigerator or at room temperature (2°C to 25°C), and is stable for the period indicated by the expiration date printed on the outer carton and pre-filled syringe label.
- Do not freeze, use product that has been frozen, or shake.
- Keep Hizentra in its original carton to protect it from light.
- Hizentra contains no preservatives and should be administered as soon as possible after opening the pre-filled syringe.

Hizentra, Subcutaneous Immunoglobulin (Human) (SCIG), is indicated for:[1]

- The treatment of patients with Primary Immune Deficiency (PID) and Secondary Immune Deficiency (SID) who require immune globulin replacement therapy.
- The treatment of patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment.

Now with a wider range of pre-filled syringe sizes to choose from:



For the 20 mL and 50 mL pre-filled syringes, screw the plunger rod onto the pre-filled syringe stopper prior to use.

CSL Behring

Hizentra®
Subcutaneous Immunoglobulin (Human), **20%**

50 mL
pre-filled syringe

Safety information[1]

Contraindications:

- Hizentra is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human normal immunoglobulin or to components of Hizentra.
- Hizentra is contraindicated in patients with hyperprolinemia type I and II because it contains the stabilizer L-proline.

Most serious warnings and precautions:

- **Hypotension:** Human normal immunoglobulin can induce a fall in blood pressure with anaphylactic reaction.
- **Thromboembolic events:** There is an association between immunoglobulin administration and events such as myocardial infarction, stroke, pulmonary embolism and deep vein thrombosis. Risk factors for thromboembolic events include advanced age, use of estrogens, in-dwelling central vascular catheters, history of vascular disease or thrombotic episodes, acquired or inherited hypercoagulable states, prolonged periods of immobilization, severe hypovolemia, diseases which increase blood viscosity and cardiovascular risk factors (including obesity, hypertension, diabetes mellitus, history of atherosclerosis and/or impaired cardiac output). Thrombosis may occur in the absence of known risk factors.

Other relevant warnings and precautions:

- Subcutaneous use only
- May contain infectious agents
- Hemolysins
- Anti-IgA antibodies
- Monitoring
- Aseptic meningitis syndrome

For more information:

Please consult the Product Monograph at https://labeling.cslbehring.ca/PM/CA/Hizentra/EN/Hizentra-Product-Monograph.pdf for contraindications, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-866-773-7721.

Reference: 1. Hizentra® Product Monograph. CSL Behring Canada Inc. February 14, 2023.

HIZ2024020383EN

CSL Behring